Document is current
Any future updates will be listed below
-
Authors
,
McKenzie, Hayley S.
Maishman, Tom
Simmonds, Peter
Durcan, Lorraine
Eccles, Diana
Copson, Ellen
- License Information
-
More Information
Article History
Received: 29 August 2019
Revised: 14 February 2020
Accepted: 25 February 2020
First Online: 31 March 2020
Ethics approval and consent to participate
: Written informed consent was obtained from all participants, and the study was performed in accordance with the Declaration of Helsinki. Ethical approval was granted in 2000 (MREC 00/6/69), and the study was approved for recruitment as part of the UK National Cancer Research Network (NCRN) portfolio in 2002, subsequently the NIHR portfolio.
: None.
: The data sets generated and/or analysed during this study are not publicly available.
: ERC declares honoraria from Roche, Astra-Zeneca, Pfizer, Lilly and Nanostring. DME declares honoraria from Astra-Zeneca and Pierre Fabre. The remaining authors declare no competing interests.
: Funding over 18 years has been provided by the Wessex Cancer Trust, Cancer Research UK (C1275/A7572, C22524, A11699 and A19187) and Breast Cancer Now (2005Nov53). HM is funded by Cancer Research UK.
